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Inflammation, in conjunction with leukocytes, plays a key role in most acute kidney
injury (AKI). Non-resolving renal inflammation leads to chronic fibrosis and renal failure.
Resolvin D series (RvDs) and E series (RvEs), protectins, and maresins (MaRs) are
endogenous omega-3 fatty acid-derived lipid mediators (LMs) that potently promote
inflammation resolution by shortening neutrophil life span and promoting macrophage
(Mf) non-phelogistic phagocytosis of apoptotic cells and the subsequent exit of Mfs
from inflammatory tissue. 14S,21R-dihydroxy docosahexaenoic acid (14S,21R-diHDHA),
a Mf-produced autacrine, reprograms Mfs to rescue vascular endothelia. RvD1, RvE1,
or 14S,21R-diHDHA also switches Mfs to the phenotype that produces pro-resolving
interleukin-10. RvDs or protectin/neuroprotectin D1 (PD1/NPD1) inhibits neutrophil
infiltration into injured kidneys, blocks toll-like receptor -mediated inflammatory activation
of Mfs and mitigates renal functions. RvDs also repress renal interstitial fibrosis, and PD1
promotes renoprotective heme-oxygenase-1 expression. These findings provide novel
approaches for targeting inflammation resolution and LMs or modulation of LM-associated
pathways for developing better clinical treatments for AKI.
Keywords: resolvins, protectins/neuroprotectins, maresins, 14S,21R-diHDHA, inflammation-resolution,
kidney-injury, fibrosis, leukocytes
ACUTE KIDNEY INJURY: AN INFLAMMATORY DISEASE
ACUTE KIDNEY INJURY: AN UNMET MEDICAL CHALLENGE
Acute kidney injury (AKI), formerly known as “acute renal fail-
ure,” causes a decline of kidney function (Bonventre and Yang,
2011). AKI occurs in many conditions, and AKI mortality is quite
significant (Bonventre and Yang, 2011). Patients with AKI have
a high chance of developing chronic or end-stage renal disease
if they survive. Pharmacologic treatment and renal replacement
therapy are only preventive or supportive and have not reduced
AKI mortality (Negi and Shigematsu, 2012). The current treat-
ment for AKI is still only preventive or supportive (Bonventre
and Yang, 2011). Kidney ischemia/reperfusion injury (KIR) is a
common cause of AKI (Bonventre and Yang, 2011).
INFLAMMATION, LEUKOCYTES, AND INFLAMMATION RESOLUTION:
CRUCIAL TO ACUTE KIDNEY INJURY AND CHRONIC FIBROSIS
Inflammation plays a critical role in pathogenesis and recovery of
AKI (Bonventre and Yang, 2011). AKI is characterized by infil-
tration and activation of leukocytes neutrophils, macrophages
(Mfs), dendritic cells (DCs), and lymphocytes as well as dam-
age (apoptosis and necrosis) of vascular endothelia and tubular
epithelia (Figure 1). The activated leukocytes produce reactive
oxidative species (ROS) and inflammatory factors, both of which
damage the surrounding tissue. Mfs and DCs participate in both
the innate and adaptive immune responses. Mfs infiltrated into
kidneys during the first 48 h after KIR are mainly inflammatory
M1 type that injures the tissue, whereas non-inflammatory M2
Mfs predominate later and are correlated with kidney repair
(Lee et al., 2011). Regulatory T-cells are protective in AKI (Ko
et al., 2010). B-cell deficiency confers protection from KIR injury
(Burne-Taney et al., 2003). This type of injury also stimu-
lates expression of adhesion molecules by vascular endothelia,
such as ICAM-1 and VCAM-1, promoting leukocyte accumu-
lation around injured sites. The injury-enhanced interaction
of endothelia and leukocytes produces inflammatory cytokines,
prostaglandins, leukotrienes, and complements, compromising
endothelial junctions due to swelling and loss of glycocalyx
and actin cytoskeleton. AKI inflammation goes into a posi-
tive feedback amplification as more blood leukocytes infiltrate
through the vascular endothelial barrier into other renal tissue
and become activated until inflammation resolution dominates
over the inflammation (Figure 1) (Borgeson and Godson, 2010;
Bonventre and Yang, 2011). Tubular epithelia, mesangium, and
pericytes also produce inflammatory factors after injury or inter-
action with leukocytes, such as TNF-α, IL-8, IL-6, and IL-1β,
leading escalated kidney inflammation and damage (Figure 1)
(Bonventre and Yang, 2011).
While leukocyte-led inflammation causes tissue injury; a nat-
ural force for inflammation resolution is gaining ground both in
parallel and in series (Serhan et al., 2002; Kieran and Rabb, 2004;
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FIGURE 1 | Role of lipid mediators, resolvins and protectins in
inflammation resolution in acute renal injury (AKI). AKI causes (1) damage
of renal vascular endothelium; (2) diapedesis of neutrophils and monocytes
through endothelium; (3) accumulation of neutrophils, macrophages (Mfs),
dendritic cells (DCs), T cells, fibroblasts, and myofibroblasts in renal tissue;
and (4) apoptosis and necrosis of tubular epithelium. Impaired inflammation
resolution that occurs during AKI leads to chronic fibrosis [i.e., excessive
extracellular matrix (ECM, as light-green lines) produced by myofibroblasts
and other cells in the kidneys] and ultimately chronic renal failure (Bonventre
and Yang, 2011; Serhan and Petasis, 2011). Although leukocytes cause tissue
damage when activated to inflammatory phenotypes by AKI in the initial
phase, they could promote inflammation resolution and tissue repair when
modulated by pro-resolving lipid mediators, including resolvins and
protectins. Resolvins, protectins, maresins, and 14S,21R-diHDHA are
produced by 12/15-lipoxygenase (LO), p450, and/or 5-LO, in trans-cellular or
intracellular biosynthetic systems of leukocytes or leukocytes plus
endothelia/epiothelia. These lipid mediators act as paracrines and autacrines
of leukocytes to promote resolution of AKI-initiated inflammation and fibrosis
and rescue of kidney functions. They also inhibit accumulation of neutrophils
and Mfs in kidneys during acute inflammation in AKI (Duffield et al., 2006;
Tian et al., 2012), promote Mf non-phlogistic efferocytosis of apoptotic
neutrophils (Hong et al., 2008), enhance apoptotic leukocyte expression of
CCR5 that scavenges critical inflammatory chemokines, and accelerate
phagocyte exit from the inflammatory site via the lymphatics (Ariel et al.,
2005; Ariel and Serhan, 2007). These lipid mediators increase the level of
pro-resolving, anti-fibrotic IL-10 and reduce the levels of inflammatory
cytokines TNFα, IL-1β, IL-6, and/or IL-8 in Mfs or renal tissue. Thus these lipid
mediators act as effectors for inflammation resolution and injury repair, which
restores AKI-damaged kidneys to homeostasis. Administration of these lipid
mediators promotes resolution of inflammation and injury in AKI.
Kluth, 2007; Serhan and Petasis, 2011). Certain macrophage phe-
notypes promote inflammation resolution in AKI (Alikhan et al.,
2011; Lee et al., 2011). Particularly, pro-resolving lipid mediators
(LMs) are produced by leukocytes or interaction of leukocytes,
endothelium, and epithelium (Hong et al., 2003; Serhan and
Petasis, 2011). These mediators trigger signaling that reduces pro-
duction of inflammatory factors, enhances non-phlogistic effero-
cytosis, and promotes the switch of inflammatory leukocytes to
pro-resolution reparative phenotypes (Figure 1, Table 1) (Hong
et al., 2008).
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Table 1 | Selected characteristics of n3-PUFAs-derived lipid mediators.
Lipid mediator Pre-cursor Enzyme(s) for Receptor(s) Activate Deactivate Inhibiting inflammatory Promoting pro-resolving
biosynthesis signaling signaling molecule expression cytokine expression
RvD1 DHA 5-LO + (12/15-LO
or 15-LO)
(a–c)
FPR2/ALXR
GPR32
(l)
IL-8 (p)
MIP-1β (p)
RANTES (p)
IL-6 (p)
VCAM-1 (p)
TNFα (q)
IL-1β (q)
IL-10 (q)
RvE1 EPA 5-LO + (12/15-LO
or 15-LO)
(c–e)
CMKLR1/
ChemR23
BLT1
(e)
PI3K
Akt
ERK1/2
(m)
NFκB (e) IL-8 (p)
VCAM-1 (p)
MIP-1β (p)
RANTES (p)
TNFα (p)
VCAM-1 (p)
IL-1β (q)
IL-10 (q)
PD1/NPD1 DHA 12/15-LO or
15-LO
(b, c, f)
PI3K
Akt
mTOR/p70S6K
(n)
NFκB (o) COX2 (r)
14S,21R-diHDHA DHA (12/15-LO or
12-LO)
+ P450
(g–k)
PI3K
Akt
p38-MAPK
(h–k)
IL-10 (i)
Notes: (a) (Serhan et al., 2002); (b) (Hong et al., 2003); (c) (Serhan and Petasis, 2011); (d) (Serhan et al., 2000); (e) (Arita et al., 2005a); (f) (Serhan et al., 2006);
(g) (Lu et al., 2010); (h) (Tian et al., 2011a); (i) (Tian et al., 2011b); (j) (Tian et al., 2010); (k) (Tian et al., 2012); (l) (Spite et al., 2009); (m) (Ohira et al., 2010); (n)
(Faghiri and Bazan, 2010); (o) (Marcheselli et al., 2003); (p) (Tian et al., 2009); (q) (Schif-Zuck et al., 2011); (r) (Mukherjee et al., 2004). BLT1, leukotriene B4 receptor;
CMKLR1/ChemR23, chemokine-like receptor 1/chemerin receptor 23; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; FPR2, formyl peptide receptor
2; GPR32, G protein-coupled receptor 32; MAPK, mitogen-activated protein kinases; MIP-1β, macrophage inflammatory protein 1β; mTOR/p70S6K, mammalian
target of rapamycin/p70 ribosomal S6 kinase; PI3K, phosphatidylinositol 3-kinase; RANTES, regulated upon activation normal T cell expressed and presumably
secreted.
Renal chronic fibrosis is the formation of excessive fibrous
connective tissue in kidneys due to excessive accumulation in
the extracellular matrix in response to chronic inflammation
or repeated injury. Although appropriate local and transient
renal fibrosis is needed for repair in the early phase of AKI,
chronic fibrosis is a major detrimental feature in the later
phases (Borgeson and Godson, 2010). Chronic fibrosis can even-
tually lead to end-stage renal failure. Leukocytes play a cru-
cial role in renal fibrosis during AKI (Borgeson and Godson,
2010) (Figure 1). Lipoxin (LX) A4, protectin/neuroprotectin D1
(PD1/NPD1), or resolvin D1 (RvD1) suppresses chronic fibro-
sis in KIR-injured kidneys (Godson et al., 2000; Duffield et al.,
2006; Borgeson and Godson, 2010; Borgeson et al., 2011). Mfs
interact with fibroblasts and pericytes, the key cells that can
transdifferentiate into fibrosis-forming myofibroblasts (Figure 1)
(Duffield, 2010). Mfs under inflammatory activation produce
pro-fibrotic factors—such as TGF-β1, IL-13, and platelet-derived
growth factor (PDGF) (Ko et al., 2008)—and also contribute
to renal fibrosis (Young et al., 1995). Moreover, Mf depletion
reduces renal fibrosis, but Mfs also can produce anti-fibrotic
factors, such as IL-10, specific matrix metalloproteinases, and
Endo180, in addition to phogocytose fibrotic extracellular matrix,
apoptotic myeofibroblasts, and tissue debris (Vernon et al., 2010).
Adoptive transfer of Mfs into mice at the chronic inflammation
phase ameliorates chronic renal fibrosis (Nishida et al., 2005).
This demonstrates that certain Mf phenotypes contribute to the
prevention or resolution of chronic renal fibrosis.
In the following sections, we will present a concise review
on omega-3 polyunsaturated fatty acids (n3-PUFA)-derived LMs
that promote the resolution of inflammation and chronic fibrosis
as well as repair in AKI.
SPECIALIZED ANTI-INFLAMMATORY, PRO-RESOLVING LIPID
MEDIATORS DERIVED FROM n3-PUFAs: RESOLVINS,
PROTECTINS, AND MARESINS (FIGURE 1, TABLE 1)
CHEMICAL STRUCTURES AND FORMATION In vivo AND In vitro
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA),
the major n3-PUFAs present in fish oils, have beneficial effects
that could prove helpful in preventing and/or treating inflamma-
tory diseases (Kelley et al., 1999; Simopoulos, 2002). As such, the
molecular and cellular mechanisms behind these beneficial effects
are of significant interest and have been explored (Bazan et al.,
1984; Serhan et al., 2000, 2002; Hong et al., 2003; Marcheselli
et al., 2003; Serhan, 2011). The structures and bioactivities
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of several families of novel n3-PUFAs-derived LMs that are
both anti-inflammatory and pro-resolving have been discovered
(Serhan, 2011). Some of these compounds were termed resolvins
since they are formed in the resolution phase of inflammation and
potently promote resolution (Serhan et al., 2002). Another DHA-
derived LM, 10,17S-docosatriene, was discovered (Serhan, 2011).
It was termed neuroprotectin D1 if generated in neural tissue for
its protection in neurons, glial cells, and brain stroke; or protectin
D1 for other tissue (Bazan, 2005; Serhan, 2011).
Resolvin D series (RvDs) are derived from DHA. During
inflammation, endogenous DHA is converted to 17S hydroxyl-
containing RvDs (RvD1–RvD6) and docosa-conjugated
triene-containing PD1/NPD1 via 15-lipoxygenase (LO)
(15S-lipoxygenation)-initiated biochemical pathways (Serhan
et al., 2002; Hong et al., 2003; Marcheselli et al., 2003) or
to 14S hydroxyl-containing maresins (MaRs) via 12-LO
(12S-lipoxygenation)-initiated biochemical pathways. 5-LO
catalyzes sequentially with 15-LO or 12/15-LO, generating
RvDs (Hong et al., 2003) and some MaRs (Serhan et al., 2009).
PD1, in isolated human cells and murine cells, was found to
be 10R,17S-dihydroxy-docosa-4Z, 7Z, 11E, 13E, 15Z, 19Z-
hexaenoic acid (Serhan et al., 2006). RvD1, RvD2, PD1/NPD1,
and/or their biosynthetical pathway marker 17S-hydroxyl DHA
(17S-HDHA) have been found in blood (Hong et al., 2003),
ischemia-injured brains, retinal pigment epithelial cells, and/or
AKI kidneys (Marcheselli et al., 2003; Mukherjee et al., 2004;
Duffield et al., 2006; Bazan et al., 2011), demonstrating the
existence of these compounds and/or pathways in injured tissue
or cells. The interaction of endothelial cells and leukocytes
promotes their biosynthesis (Tian et al., 2009) (Figure 1). RvE1
and 17R-hydroxyl epimers of RvDs and PD1, on the other hand,
are generated through 15R-lipoxygenation pathways catalyzed by
aspirin-acetylated cyclocygenase-2 (COX-2) or cytochrome P450
(in contrast to the typical 15-LO-catalyzed 15S-lipoxygenation of
arachidonic acid) (Serhan et al., 2000, 2006). They were found
in exudates, blood, and brains of humans and animals treated
with aspirin (Serhan, 2011; Bazan et al., 2012). This provides
new molecular insights for aspirin-based anti-inflammatory
medication besides inhibiting COXs to produce inflammatory
prostaglandins and thromboxins.
Recently we found several additional new pro-healing LMs:
14S,21R-dihydroxy-docosa-4Z, 7Z, 10Z, 12E, 16Z, 19Z-hexaenoic
acid (14S,21R-diHDHA) and its epimers (Lu et al., 2010; Tian
et al., 2011a,b). 14S,21R-diHDHA, as a positional isomer of
maresin-1 (Serhan et al., 2009), is generated from DHA in Mfs,
neutrophils, and cutaneous wounds. 12-LO and P450 catalyze
sequentially to convert DHA to 14S,21R-diHDHA and 14S,21S-
diHDHA through the intermediacy of 14S-HDHA (formed via
12S-lipoxygenation from DHA) (Lu et al., 2010; Tian et al.,
2011a).
BIOACTIONS
Resolvins, protectins, andMaRs recapitulate beneficial bioactions
of DHA or EPA with several order-of-magnitudes higher potency
(in nanomolar and picomolar range) compared to their precur-
sors (DHA or EPA) (Serhan and Petasis, 2011). These LMs have
potent anti-inflammatory and pro-resolving effects, since they
inhibit inflammatory factor expression and neutrophil infiltra-
tion, and since they promote non-phlogistic Mf phagocytosis of
apoptotic cells (Serhan and Petasis, 2011). Such actions have been
revealed in many in vivo models of inflammatory diseases, as
well as in vitro experiments on diverse types of cells critical to
these diseases. These actions include dermal inflammation, peri-
tonitis, periodontitis, colitis and intestinal inflammation, asthma
and airway inflammation, cystic fibrosis, acute lung or kidney
injury, glomerulonephritis, and brain stroke (Marcheselli et al.,
2003; Serhan and Petasis, 2011). RvE1 and its analogs are cur-
rently undergoing clinic trials for diseases of the eye, lung, kidney,
skin, and intestines (Serhan and Petasis, 2011). Bazan et al. dis-
covered that PD1/NPD1 resolves inflammation in brain and eye
(Marcheselli et al., 2003; Mukherjee et al., 2004; Lukiw et al.,
2005). PD1 or LXA4 blocks inflammatory cytokine secretion
from human T-cells and enhances CCR5 expression on apoptotic
PMN (Figure 1), which accelerates clearance of inflammatory
CCR5 ligands (Ariel et al., 2003, 2005). PD1 also promotes T-cell
apoptosis (Ariel et al., 2005), as well as reduces the neutrophil
lifespan in peritonitis (Bannenberg et al., 2005) and neutrophil-
survival signaling for IL-1β (Hong et al., 2003). RvE1 promotes
phagocytosis-induced neutrophil apoptosis and resolution of pul-
monary inflammation (El Kebir et al., 2012). Several comprehen-
sive reviews on these mediators are already available (Borgeson
and Godson, 2010; Serhan and Petasis, 2011; Bazan, 2012).
14S,21-diHDHA and 14R,21-diHDHA promote or restore
wound healing (Lu et al., 2010) impaired by alcohol intoxica-
tion (Tian et al., 2010) or diabetes (Tian et al., 2011a). Also,
14S,21R-diHDHA enhances VEGF release, vascularization, and
migration of endothelial cells in diabetic mice. It also reme-
dies angiogenic and pro-healing functions of mesenchymal stem
cells (MSCs) and Mfs attenuated by diabetes, including their
production of VEGF and/or IL-10 (Tian et al., 2011b). 14S,21R-
diHDHA reduces hyperglycemia-induced ROS generation by
inflammatorily-activated Mfs (Tian et al., 2011b). Thus, 14S,21R-
diHDHA is a specific pro-resolving LM that may promote the
protection or repair of the renal endothelium and epithelium
during AKI.
RECEPTORS (TABLE 1)
Two G-protein-coupled receptors have been identified for RvE1:
(1) BLT1 in neutrophils; and (2) CMKLR1/ChemR23 in Mfs and
DCs (Arita et al., 2005a,b). RvD1 has also been reported to inter-
act with both FPR2 or LXA4 receptor (ALXR) and GPR32 in
phagocytes (Spite et al., 2009). ALXR is expressed in neutrophils
(Fiore et al., 1994) and monocytes (Maddox et al., 1997), and
it activates T-cells (Ariel et al., 2003), intestinal or bronchial
epithelial cells (Bonnans et al., 2003; Kucharzik et al., 2003),
and renal mesangial cells (McMahon et al., 2000; Maderna and
Godson, 2009), implying ALXR existence in renal podocytes and
tubular epithelium. PD1/NPD1 stereoselectively and specifically
binds with retinal pigment epithelial cells and neutrophils, sug-
gesting specific receptors for NPD1 in both the immune and
visual systems (Marcheselli et al., 2010). However, the exact
NPD1 receptor(s) needs to be identified. The receptors of other
resolvins, protectins, and marsins are likely to exist based on their
structure-activity association, but have not been discovered yet.
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CELL SIGNALING (TABLE 1)
Through CMKLR1 or BLT1 receptors, RvE1 represses the acti-
vation of NFκB (Arita et al., 2005a, 2007), a crucial regulator
of innate immune responses in kidneys (Mulay et al., 2012).
NPD1 or RvE1-CMKLR1 interactions activate PI3K and Akt,
which involves mTOR signaling; RvE1 also activates ERK1/2
(Faghiri and Bazan, 2010; Ohira et al., 2010). 14S,21R-diHDHA
activates PI3K, Akt, and P38-MAPK, but not ERK1/2 (Tian et al.,
2010, 2011a, 2012). PI3K-Akt signaling regulates cell survival, and
activation of MAPK pathways is essential in wound healing and
associated angiogenesis (Tian et al., 2010, 2011a). These signaling
systems are relevant to AKI (Borgeson and Godson, 2010; Tian
et al., 2012).
METABOLIC DEACTIVATION
RvD1 is converted by eicosanoid oxidoreductases (EORs) to
17-oxo-RvD1 and 8-oxo-RvD1. The former is an inactivation
metabolite, while the latter is still effective in suppressing neu-
trophil infiltration (Sun et al., 2007). RvE1 is metabolized
to 12-oxo-RvE, 18-oxo-RvE1, 10,11-dihydroxy RvE, 19-hydroxy
RvE1, 20-hydroxy RvE1 in tissue or cells, of which the first four
metabolites are inactive partially or completely in inflamma-
tion resolution, and thus are representative for RvE1 metabolic
deactivation (Arita et al., 2006; Hong et al., 2008). Human neu-
trophils convert PD1 to its omega-22 hydroxy product (Serhan
and Petasis, 2011). The metabolic deactivation of resolvins could
be excessively up-regulated in pathological conditions, resulting
in their deficiency, or diminishing the pharmacological efficacy of
administered resolvins. Molecular engineering has been used to
overcome this problem; for example, A p-fluorophenoxyl added
to RvE1 ω-terminal blocks the critical metabolic inactivation of
RvE1 without attenuating the anti-inflammatory pro-resolving
activities (Arita et al., 2005a; Hong et al., 2008).
RESOLVIN D SERIES AND PROTECTIN D1 RESOLVE
INFLAMMATION ANDMITIGATE AKI (FIGURE 1, TABLE 1)
Based on the findings that DHA-derived RvDs and PD1 promote
inflammation resolution (Serhan, 2011) and DHA supplementa-
tion reduces KIR injury in dogs and rats (Neumayer et al., 1992;
Kielar et al., 2003), Duffield and colleagues studied the treat-
ment of murine KIR with RvDs and PD1. The study showed
that administration of RvDs (RvD1:RvD2:RvD3 = 1:2:1), RvD1,
or PD1 attenuates functional and morphological kidney injury,
reduces accumulation of inflammatory neutrophils and Mfs, and
suppresses TLR-mediated activation of Mfs. TLR signaling in
Mfs and lymphocytes is involved in sustained chronic inflam-
mation (Foell et al., 2007; Kato et al., 2008). RvDs treatment
until 72 h after ischemia inhibits renal interstitial chronic fibrosis
(Duffield et al., 2006). Interstitial chronic fibrosis and persis-
tent leukocyte infiltration (chronic inflammation), resulting from
AKI, leads to scarring and chronic renal failure (Morgera et al.,
2002; Duffield and Bonventre, 2004). RvDs and PD1 likely have
additional cellular sites of action in the kidney, e.g., on the
endothelium and vascular tone, interstitial fibroblasts, mesangial
cells, pericytes, DCs, and T-cells because of their pro-resolving
and anti-fibrotic ability (Duffield et al., 2006). They may modu-
late the actions of monocytes/Mfs and neutrophils in the kidney.
Hassan and Gronert found that PD1 amplified renoprotective
heme-oxygenase-1 (HO-1) expression in ischemia-injured and
non-injured kidneys, while PD1 inhibited neutrophil infiltra-
tion in murine KIR (Hassan and Gronert, 2009). These results
support their notion that the interaction of the 12/15-LO and
HO-1 systems provides a positive feedback loop that amplifies
anti-inflammatory, pro-resolving signals.
Godson and colleagues found that arachidonic acid-derived
LXs are pro-resolving in several types of renal injury; LXs play
a reparative role in glomerulonephritis, and reduce protein-
uria, glomerular inflammation, and mesangial cell proliferation
(Kieran et al., 2004; Wu et al., 2006; Borgeson and Godson, 2010).
LXs are protective against murine KIR, where a LX-stable ana-
logue gives functional and morphological protection and atten-
uates inflammatory cytokine responses (Leonard et al., 2002).
LXs also up-regulate genes of tight-junction proteins claudin 1,
3, and 7, which likely reduce inflammatory leukocyte infiltration;
Moreover, they found that LXs attenuate renal chronic fibrosis
and related gene expression in mesangial cells (Borgeson and
Godson, 2010). LXA4 analog or RvE1 remarkably prolong renal
allograft survival in mice, which is consistent with LXA4 inhibi-
tion of calcineurin activity and inflammatory cytokine release by
human neutrophils. Also, RvE1 counter-regulates leukocytes par-
tially via increased LXA4 biosynthesis (Levy et al., 2011). Since
AKI is the major complication of renal allograft transplantation
(Bellomo et al., 2012), these results further demonstrate the effec-
tiveness of LXA4 or RvE1 in reducing AKI. LX actions converge
with the pro-resolving characteristics of RvD1, as LXA4 and RvD1
both activate the same G-protein coupled receptors ALXR/FPR2
and GPR32.
14S,21R-diHDHA PROMOTES MESENCHYMAL STEM CELLS
IN RESOLUTION OF INFLAMMATION AND PREVENTION
OF AKI
MSCs have shown potential to resolve inflammation and repair
injury in renal failure (Togel et al., 2005). MSCs treated with
14S,21R-diHDHAmore efficiently inhibit KIR-induced elevation
of serum creatinine levels and reduce renal tubular cell death,
as well as infiltration of neutrophils, Mfs, and DCs to renal tis-
sue. Conditioned media from 14S,21R-diHDHA-treated MSCs
reduce the generation of TNF-α and ROS by Mfs under KIR con-
ditions. Infusion of 14S,21R-diHDHA-treated MSCs more effi-
ciently reduce KIR-renal damage compared to untreated MSCs.
Treated MSCs are resistant to apoptosis in vivo (when trans-
planted under capsules of AKI-injured kidneys) and in vitro
(when cultured under simulated KIR conditions). This enhance-
ment of MSC viability involves PI3K-Akt signaling. Additionally,
treatment of MSCs with 14S,21R-diHDHA promotes secretion of
renotrophic hepatocyte growth factor and insulin growth factor-
1. In brief, 14S,21R-diHDHApromotes MSC amelioration of AKI
(Tian et al., 2012).
RESOLVINS, PROTECTINS, AND MARESINS ACT ON
LEUKOCYTES RELATED TO FIBROSIS IN AKI
Although the mechanisms that resolvins and PD1 use to reduce
renal chronic fibrosis in AKI (Duffield et al., 2006) remain to be
further delineated, the following findings provide hints for future
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research on this subject. PD1, RvD1, or RvE1 switches Mfs
to pro-resolving phenotypes, including CD11blow Mfs, which
are more capable in efferocytosis and emigration to lymphoid
organs for inflammation resolution (Figure 1) (Schwab et al.,
2007; Schif-Zuck et al., 2011; Ariel and Serhan, 2012). RvD1,
RvE1, or 14S,21R-diHDHA induces Mfs to produce more anti-
fibrotic IL-10 (Schif-Zuck et al., 2011; Tian et al., 2011b). These
pro-resolving LMs, acting in concert in AKI, not only inhibit
inflammation, but also shift the macrophage roles from pro-
inflammatory (M1) or pro-fibrotic phenotypes to phenotypes
that promote resolution as well as anti-fibrotic, regulatory func-
tions (Figure 1, Table 1) (Duffield et al., 2006; Serhan and Petasis,
2011; Ariel and Serhan, 2012).
CONCLUDING REMARKS AND PERSPECTIVES
The discoveries of n3-PUFA-derived resolvins, protectins, and
MaRs in the last two decades have provided unconventional
knowledge and opened new frontiers for understanding the
mechanisms involved in inflammation resolution. These LMs
are produced endogenously by enzymes in leukocytes and tissue
and act as paracrines and autacrines of leukocytes. Experiments
have already shown that selected LMs promote resolution of
AKI-caused inflammation and chronic fibrosis and rescue kidney
function. LMs inhibit recruitment of neutrophils and mono-
cytes to kidneys during acute inflammation, and they likely
switch Mfs and T-cells toward anti-inflammatory pro-resolving
phenotypes in AKI, as observed in other inflammatory con-
ditions (Figure 1, Table 1). Mechanisms behind the actions of
these LMs and their regulatory roles on leukocytes provide the
basis for developing leukocyte-related modalities for efficient
AKI treatment. These LMs or their mimics may be of thera-
peutic importance for treating AKI. More studies need to be
conducted to further delineate the kinetic process for these LMs
in reprogramming the phenotypes of leukocytes, which regulate
the resolution of renal inflammation and chronic fibrosis and
recover renal functions in AKI. Additional up-stream or down-
stream signaling pathways involved should also be studied, as
they may yield novel mechanistic targets and insights for AKI
treatment.
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